Neuroprotective Potential of Nutraceuticals in Managing Neurodegenerative Disorders

Abstract

Nutraceuticals, a broad category of food-derived products with possible health advantages, have attracted a lot of
interest in the treatment of neurodegenerative diseases (NDDs), including multiple sclerosis, Parkinson’s disease,
and Alzheimer’s disease. These disorders present considerable therapeutic challenges because of their complex
etiology and limited treatment choices. They are characterized by progressive neuronal degeneration and related
motor and cognitive impairments. Because of their capacity to alter different biochemical and molecular pathways
linked to neurodegeneration, nutraceuticals play a crucial role in managing non-alcoholic fatty liver disease NDD.
Important processes include control of protein aggregation, antioxidative stress, anti-inflammatory effects, and
mitochondrial protection. Pre-clinical and clinical research have demonstrated the potential neuroprotective effects
of compounds, such as omega-3 fatty acids, polyphenols (such as curcumin and resveratrol), and vitamins (such as
Vitamin E and Vitamin D). Furthermore, as a supplementary strategy to traditional treatments, nutraceuticals have
the ability to improve therapeutic results and halt the advancement of disease. Their accessibility, natural origin,
and usually acceptable safety profile make them appealing candidates for long-term usage in the management
of NDDs notwithstanding its potential, variables, including bioavailability, dose optimization, and response
variability, pose challenges to the therapeutic use of nutraceuticals in NDDs. To create uniform dosages, clarify the
mechanisms of action, and confirm their efficacy through well-planned clinical studies, more research is required.